Chinese drug quality audits are typically conducted annually by the National Medical Products Administration (NMPA). However, the frequency can vary based on risk assessments, with more frequent inspections for high-risk facilities or products. Additionally, unannounced inspections may occur to ensure compliance with Good Manufacturing Practices (GMP) and regulatory standards.